Clinical trials: Canthal Lines
Glabellar Frown Lines, Canthal Lines
Assess Aesthetic Improvement With QM1114-DP in Subjects With Moderate to Severe Lateral Canthal Lines and Glabellar Lines
This study to assess aesthetic improvement following treatment with QM1114-DP.
- Trial name
- NCT05148000
- Testing
- QM1114-DP
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Galderma R&D
Lateral Canthal Lines
Treatment of Moderate to Severe Lateral Canthal Lines
The objective of the study is to evaluate the efficacy and safety of a single dose of QM1114-DP compared to placebo for the treatment of moderate to severe LCL.
- Trial name
- READY-2 (NCT04249687)
- Testing
- botulinum toxin
- Where
- 10 sites in United States, Canada
- Volunteers
- 303 people, healthy volunteers welcome
- Sponsor
- Galderma R&D
Lateral Canthal Lines, Crow's Feet
ET-01 in Subjects With Lateral Canthal Lines, LCL-208
This study tests an investigational drug formulation called ET-01, botulinum toxin, Type A, topical, in lateral canthal lines (LCL).
- Trial name
- NCT03839693
- Testing
- botulinum toxin, Type A, Vehicle
- Where
- 5 sites in United States
- Volunteers
- 75 people
- Sponsor
- Eirion Therapeutics Inc.
Glabellar Lines, Lateral Canthal Lines
MT10109L in the Long-term, Open-label Treatment of Glabellar Lines (GL) and Lateral Canthal Lines (LCL)
To evaluate the long-term safety of MT10109L in the treatment of GL and/or LCL in participants with moderate to severe GL and/or LCL.
- Trial name
- NCT04157686
- Testing
- MT10109L Dose 1, MT10109L Dose 2, MT10109L Dose 1 + Dose 2
- Where
- 38 sites in United States, Belgium and 4 more
- Volunteers
- 957 people
- Sponsor
- Medy-Tox
Lateral Canthal Lines, Crow's Feet Lines
BOTOX® in the Treatment of Crow's Feet Lines in China
This study will evaluate the safety and efficacy of BOTOX® (botulinum toxin Type A) compared with placebo in patients with moderate to severe crow's feet lines (lateral canthal lines).
- Trial name
- NCT02195687
- Testing
- botulinum toxin Type A, Normal Saline
- Where
- China
- Volunteers
- 417 people
- Sponsor
- Allergan
Upper Facial Lines (Glabellar Lines, Forehead Lines, & Lateral Canthal Lines)
Efficacy and Safety of DaxibotulinumtoxinA (DAXI) for Injection for Treatment of Upper Facial Lines
This is a Phase 2, multicenter, open-label, single-arm study to evaluate the efficacy and safety of DaxibotulinumtoxinA for injection (DAXI for injection) in the treatment of Glabellar Lines (GL), Dynamic Forehead Lines (FHL)…
- Trial name
- NCT04259086
- Testing
- DaxibotulinumtoxinA for injection
- Where
- 8 sites in United States, Canada
- Volunteers
- 48 people
- Sponsor
- Revance Therapeutics, Inc.
Facial Rhytides, Glabellar Rhytides
A Safety and Efficacy Study of OnabotulinumtoxinA in Upper Facial Rhytides
This is a safety and efficacy study of onabotulinumtoxinA in subjects with upper facial rhytides (forehead lines, glabellar lines, lateral canthal lines [crow's feet lines]).
- Trial name
- NCT02261493
- Testing
- OnabotulinumtoxinA, Normal Saline
- Where
- 24 sites in United States, Belgium and 2 more
- Volunteers
- 787 people
- Sponsor
- Allergan
Upper Facial Lines
A Study to Evaluate Participant Satisfaction and Natural Outcomes Following Administration of BOTOX Cosmetic Injections in Adult Participants for Treatment of Upper Facial Lines
Facial lines that develop from repeated facial expression, such as glabellar lines (GL), lateral canthal lines (LCL), and forehead lines (FHL), are typically treated by selectively weakening specific muscles with small quantities…
- Trial name
- UFL BOND 974 (NCT06218251)
- Testing
- BOTOX
- Where
- 10 sites in United States, Canada
- Volunteers
- 100 people
- Sponsor
- AbbVie
Lateral Canthal Lines
MT10109L in the Treatment of Lateral Canthal Lines
To evaluate the safety and efficacy of MT10109L in the treatment of lateral canthal lines (LCL) in participants with moderate to severe LCL.
- Trial name
- NCT03785145
- Testing
- MT10109L
- Where
- 14 sites in United States, Russia and 1 more
- Volunteers
- 235 people
- Sponsor
- Medy-Tox
Glabellar Lines, Lateral Canthal Lines
MT10109L in the Treatment of Glabellar Lines (GL) With or Without Concurrent Treatment of Lateral Canthal Lines (LCL)
To evaluate the safety and efficacy of MT10109L for the treatment of glabellar lines (GL) with or without concurrent treatment of lateral canthal lines (LCL) in participants with moderate to severe GL and LCL.
- Trial name
- NCT03721016
- Testing
- MT10109L
- Where
- 21 sites in United States, Canada and 2 more
- Volunteers
- 415 people
- Sponsor
- Medy-Tox
Lateral Canthal Lines, Crow's Feet
ET-01 in Subjects With Lateral Canthal Lines
This study tests an investigational drug formulation called ET-01, botulinum toxin, Type A, topical, in lateral canthal lines (LCL).
- Trial name
- NCT03326856
- Testing
- botulinum toxin, Type A, Vehicle
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Eirion Therapeutics Inc.
Glabellar Lines, Lateral Canthal Lines
Long-term Treatment of Moderate to Severe Glabellar Lines and Lateral Canthal Lines
This is a phase 3, multicenter, open-label study to evaluate the safety of QM1114-DP for the long term treatment of moderate to severe Glabellar (Frown) Lines (GL) and Lateral Canthal Lines (Crow's Feet and LCL).
- Trial name
- READY-4 (NCT04225260)
- Testing
- botulinum toxin neuromodulator
- Where
- 30 sites in United States, Puerto Rico
- Volunteers
- 902 people, healthy volunteers welcome
- Sponsor
- Galderma R&D
Moderate to Severe Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines, and Lateral Canthal Lines)
Safety and Efficacy Study of the Simultaneous Treatment of Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines and Lateral Canthal Lines) in Subjects With Moderate to Severe Upper Facial Lines
The purpose of this study is to investigate the safety and efficacy of NT 201 (active ingredient: Botulinum (neuro)toxin type A, free from complexing proteins) in the combined treatment of wrinkles in the upper face (Upper Facial…
- Trial name
- ULTRA I (NCT04594213)
- Testing
- NT 201
- Where
- 12 sites in United States
- Volunteers
- 362 people
- Sponsor
- Merz North America, Inc.
Lateral Canthal Lines, Glabellar Lines
MT10109L in the Treatment of Lateral Canthal Lines With or Without Concurrent Treatment of Glabellar Lines
To evaluate the safety and efficacy of MT10109L for the treatment of lateral canthal lines (LCL) with or without concurrent treatment of glabellar lines (GL) in participants with moderate to severe LCL and GL.
- Trial name
- NCT03732833
- Testing
- MT10109L
- Where
- 20 sites in United States, Canada and 1 more
- Volunteers
- 425 people
- Sponsor
- Medy-Tox
Lateral Canthal Lines, Crow's Feet
ET-01 in Subjects With Lateral Canthal Lines, LCL-207
This study tests an investigational drug formulation called ET-01, botulinum toxin, Type A, topical, in lateral canthal lines (LCL).
- Trial name
- NCT03655691
- Testing
- Vehicle, botulinum toxin, Type A
- Where
- 6 sites in United States
- Volunteers
- 79 people
- Sponsor
- Eirion Therapeutics Inc.
Glabellar Frown Lines (GL), Lateral Canthal Lines (LCL)
Treatment of Moderate to Severe Lateral Canthal Lines and Glabellar Lines Alone or in Combination
This study is designed to evaluate the safety and efficacy of a single dose of QM1114-DP for the treatment of moderate to severe LCL and moderate to severe GL, alone or in combination.
- Trial name
- READY-3 (NCT04247074)
- Testing
- botulinum toxin neuromodulator
- Where
- 12 sites in United States, Canada
- Volunteers
- 413 people, healthy volunteers welcome
- Sponsor
- Galderma R&D
Lateral Canthal Lines
Efficacy and Safety of Increasing Doses of DaxibotulinumtoxinA for Injection (DAXI for Injection) in the Treatment of Moderate or Severe Lateral Canthal Lines
A Phase 2a, Multicenter, Open-Label, Dose-Escalation Study to Evaluate the Treatment of Moderate or Severe Lateral Canthal Lines (LCL).
- Trial name
- NCT03911102
- Testing
- DaxibotulinumtoxinA for injection
- Where
- 4 sites in United States
- Volunteers
- 63 people
- Sponsor
- Revance Therapeutics, Inc.
Lateral Canthal Lines, LCL, Crow's Feet
ET-01 in Subjects With Lateral Canthal Lines, LCL-209
This study tests an investigational drug formulation called ET-01, botulinum toxin, Type A, topical, in lateral canthal lines (LCL).
- Trial name
- NCT03912805
- Testing
- botulinum toxin, Type A, Vehicle
- Where
- 3 sites in United States
- Volunteers
- 38 people
- Sponsor
- Eirion Therapeutics Inc.
Moderate to Severe Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines, and Lateral Canthal Lines)
Safety and Efficacy Study of the Simultaneous Treatment of Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines and Crows Feet) in Subjects With Moderate to Severe Upper Facial Lines
The purpose of this study is to investigate the safety and efficacy of NT 201 (active ingredient: Botulinum (neuro)toxin type A, free from complexing proteins) in the combined treatment of wrinkles in the upper face (Upper Facial…
- Trial name
- ULTRA II (NCT04622254)
- Testing
- NT 201
- Where
- 12 sites in Germany
- Volunteers
- 368 people
- Sponsor
- Merz North America, Inc.
Canthal Lines
A Multi-Center Study Of CD07743 for the Improvement of Lateral Canthal Lines (CROW'S FEET)
This double-blind study has two parts for each subject (same population): Part A: initial treatment in Lateral Canthal Lines (LCL) (placebo-controlled): To assess the efficacy and safety of Azzalure® compared to placebo in the…
- Trial name
- NCT01308060
- Testing
- Botulinum Toxin Type A
- Volunteers
- 335 people
- Sponsor
- Galderma R&D